Lieberman JA, Stroup TS, Perkins DO et al (2006) The American Psychiatric Publishing textbook of schizophrenia 1st ed. American Psychiatric Pub., Washington DC, pp xvii, 435 p.
Newcomer JW, Hennekens CH (2007) Severe mental illness and risk of cardiovascular disease. JAMA 298:1794–6.PubMed
Colton CW, Manderscheid RW (2006) Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 3:A42.PubMedCentralPubMed
Ratliff JC, Palmese LB, Reutenauer EL et al (2012) The effect of dietary and physical activity pattern on metabolic profile in individuals with schizophrenia: a cross-sectional study. Compr Psychiatry 53:1028–33.PubMedCentralPubMed
Strassnig M, Brar JS, Ganguli R (2003) Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 29:393–7.PubMed
Beebe LH, Tian L, Morris N et al (2005) Effects of exercise on mental and physical health parameters of persons with schizophrenia. Issues Ment Health Nurs 26:661–76.PubMed
El-Mallakh P (2007) Doing my best: poverty and self-care among individuals with schizophrenia and diabetes mellitus. Arch Psychiatr Nurs 21:49–60; discussion 61–3.PubMed
Beebe LH (2008) Obesity in schizophrenia: screening, monitoring, and health promotion. Perspect Psychiatr Care 44:25–31.PubMed
Mitchell AJ, Vancampfort D, Sweers K et al (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull 39:306–18.PubMedCentralPubMed
Poirier P, Giles TD, Bray GA et al (2006) Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 26:968–76.PubMed
Cohn TA, Remington G, Zipursky RB et al (2006) Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. Can J Psychiatry 51:382–6.PubMed
Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284–9.PubMed
Spelman LM, Walsh PI, Sharifi N et al (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 24:481–5.PubMed
Verma SK, Subramaniam M, Liew A et al (2009) Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry 70:997–1000.PubMed
Maayan L, Vakhrusheva J, Correll CU (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and metaanalysis. Neuropsychopharmacology 35:1520–30.PubMedCentralPubMed
Leucht S, Corves C, Arbter D et al (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41.PubMed
Osby U, Correia N, Brandt L et al (2000) Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45:21–8.PubMed
Scheen AJ, De Hert MA (2007) Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 33:169–75.PubMed
Fenton WS, Chavez MR (2006) Medication-induced weight gain and dyslipidemia in patients with schizophrenia. Am J Psychiatry 163:1697–704; quiz 1858–9.PubMed
Huang TL, Chen JF (2005) Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res 80:55–9.PubMed
Ahmed M, Hussain I, O’Brien SM et al (2008) Prevalence and associations of the metabolic syndrome among patients prescribed clozapine. Ir J Med Sci 177:205–10.PubMed
Weiden PJ, Newcomer JW, Loebel AD et al (2008) Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 33:985–94.PubMed
Mukundan A, Faulkner G, Cohn T et al (2010) Antipsychotic switching for people with schizophrenia who have neurolepticinduced weight or metabolic problems. Cochrane Database Syst Rev CD0066–9.
Addington J, Mansley C, Addington D (2003) Weight gain in first-episode psychosis. Can J Psychiatry 48:272–6.PubMed
De Hert M, Dobbelaere M, Sheridan EM et al (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry 26:144–158.PubMed
Tarricone I, Ferrari Gozzi B, Serretti A et al (2010) Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med 40:187–200.PubMed
Das C, Mendez G, Jagasia S et al (2012) Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Annals of Clinical Psychiatry 24:225–39.PubMed
Gebhardt S, Theisen FM, Haberhausen M et al (2010) Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther 35:207–11.PubMed
Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 125:169–79.PubMed
De Hert M, Detraux J, Van Winkel R et al (2012) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology 8:114–126.
Stip E, Lungu OV, Anselmo K et al (2012) Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl Psychiatry 2:e1–8.
Daumit GL, Crum RM, Guallar E et al (2003) Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry 60:121–8.PubMed
Mojtabai R, Olfson M (2010) National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 67:26–36.PubMed
McEvoy JP, Meyer JM, Goff DC et al (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19–32.PubMed
Dixon L, Weiden P, Delahanty J et al (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:903–12.PubMed
Grundy SM, Brewer HB Jr., Cleeman JI et al (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433–8.PubMed
Meyer JM, Koro CE (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1–17.PubMed
Ekblom-Bak E, Hellenius ML, Ekblom O et al (2010) Independent associations of physical activity and cardiovascular fitness with cardiovascular risk in adults. Eur J Cardiovasc Prev Rehabil 17:175–80.PubMed
Aspenes ST, Nilsen TI, Skaug EA et al (2011) Peak oxygen uptake and cardiovascular risk factors in 4631 healthy women and men. Med Sci Sports Exerc 43:1465–73.PubMed
Kodama S, Saito K, Tanaka S et al (2009) Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 301:2024–35.PubMed
Dvorak RV, Tchernof A, Starling RD et al (2000) Respiratory fitness, free living physical activity, and cardiovascular disease risk in older individuals: a doubly labeled water study. J Clin Endocrinol Metab 85:957–63.PubMed
Wisloff U, Ellingsen O, Kemi OJ (2009) High-intensity interval training to maximize cardiac benefits of exercise training? Exerc Sport Sci Rev 37:139–46.PubMed
Myers J, Prakash M, Froelicher V et al (2002) Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 346:793–801.PubMed
Blair SN, Kohl HW, Barlow CE et al (1995) Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA 273:1093–8.PubMed
Ekelund LG, Haskell WL, Johnson JL et al (1988) Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study. N Engl J Med 319:1379–84.PubMed
Scheewe TW, Takken T, Kahn RS et al (2012) Effects of exercise therapy on cardiorespiratory fitness in patients with schizophrenia. Med Sci Sports Exerc 44:1834–42.PubMed
Strassnig M, Brar JS, Ganguli R (2011) Low cardiorespiratory fitness and physical functional capacity in obese patients with schizophrenia. Schizophrenia Research 126:103–109.PubMedCentralPubMed
Filik R, Sipos A, Kehoe PG et al (2006) The cardiovascular and respiratory health of people with schizophrenia. Acta Psychiatr Scand 113:298–305.PubMed
Nyboe L, Lund H (2013) Low levels of physical activity in patients with severe mental illness. Nord J Psychiatry 67:43–6.PubMed
Bajaj JS, Ratliff SM, Heuman DM et al (2012) Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther 36:866–74.PubMedCentralPubMed
Sharpe JK, Stedman TJ, Byrne NM et al (2006) Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry 40:810–4.PubMed
Papanastasiou E (2012) Interventions for the metabolic syndrome in schizophrenia: A review. Therapeutic Advances in Endocrinology and Metabolism 3:141–162.PubMedCentralPubMed
Maayan L, Correll CU (2010) Management of antipsychoticrelated weight gain. Expert Rev Neurother 10:1175–200.PubMedCentralPubMed
Henderson DC, Copeland PM, Daley TB et al (2005) A doubleblind, placebo-controlled trial of sibutramine for olanzapineassociated weight gain. Am J Psychiatry 162:954–62.PubMed
Graham KA, Gu H, Lieberman JA et al (2005) Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 162:1744–6.PubMed
Ko YH, Joe SH, Jung IK et al (2005) Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 28:169–75.PubMed
Ghanizadeh A, Nikseresht MS, Sahraian A (2013) The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: A randomized, double-blind, placebocontrolled clinical trial. Schizophr Res 147:110–5.PubMed
Wu RR, Zhao JP, Jin H et al (2008) Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 299:185–93.PubMed
Ganguli R (2007) Behavioral therapy for weight loss in patients with schizophrenia. J Clin Psychiatry 68 Suppl 4:19–25.PubMed
Carroll S, Dudfield M (2004) What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. Sports Med 34:371–418.PubMed
Church TS, Earnest CP, Skinner JS et al (2007) Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. JAMA 297:2081–91.PubMed
Duscha BD, Slentz CA, Johnson JL et al (2005) Effects of exercise training amount and intensity on peak oxygen consumption in middle-age men and women at risk for cardiovascular disease. Chest 128:2788–93.PubMed
Messier V, Brazeau AS, Rabasa-Lhoret R et al, Physical exercise in the prevention and treatment of obesity, diabetes and metabolic syndrome, in Nutritional and metabolic bases of cardiovascular disease2011, Wiley-Blackwell: Chichester, West Sussex; Hoboken, NJ.
McArdle WD, Katch FI, Katch VL (2010) Exercise physiology: nutrition, energy, and human performance 7th ed. Lippincott Williams & Wilkins, Baltimore MD, pp lxv, 1038
Willis LH, Slentz CA, Bateman LA et al (2012) Effects of aerobic and/or resistance training on body mass and fat mass in overweight or obese adults. J Appl Physiol 113:1831–7.PubMedCentralPubMed
Johnson JL, Slentz CA, Houmard JA et al (2007) Exercise training amount and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise). Am J Cardiol 100:1759–66.PubMedCentralPubMed
Dumortier M, Brandou F, Perez-Martin A et al (2003) Low intensity endurance exercise targeted for lipid oxidation improves body composition and insulin sensitivity in patients with the metabolic syndrome. Diabetes Metab 29:509–18.PubMed
Caro J, Navarro I, Romero P et al (2013) Metabolic effects of regular phisical exercice in healthy population. Endocrinol Nutr
Helmrich SP, Ragland DR, Leung RW et al (1991) Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 325:147–52.PubMed
Sakurai T, Ogasawara J, Kizaki T et al (2012) Preventive and improvement effects of exercise training and supplement intake in white adipose tissues on obesity and lifestyle-related diseases. Environ Health Prev Med 17:348–56.PubMedCentralPubMed
Gibala MJ, McGee SL (2008) Metabolic adaptations to short-term high-intensity interval training: a little pain for a lot of gain? Exerc Sport Sci Rev 36:58–63.PubMed
Kessler HS, Sisson SB, Short KR (2012) The potential for highintensity interval training to reduce cardiometabolic disease risk. Sports medicine (Auckland N.Z.) 42:489–509.
Tjonna AE, Lee SJ, Rognmo O et al (2008) Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study. Circulation 118:346–54.PubMedCentralPubMed
Tjonna AE, Stolen TO, Bye A et al (2009) Aerobic interval training reduces cardiovascular risk factors more than a multitreatment approach in overweight adolescents. Clin Sci (Lond) 116:317–26.
Hwang CL, Wu YT, Chou CH (2011) Effect of aerobic interval training on exercise capacity and metabolic risk factors in people with cardiometabolic disorders: a meta-analysis. J Cardiopulm Rehabil Prev 31:378–85.PubMed
Sassen B, Cornelissen VA, Kiers H et al (2009) Physical fitness matters more than physical activity in controlling cardiovascular disease risk factors. Eur J Cardiovasc Prev Rehabil 16:677–83.PubMed
Trapp EG, Chisholm DJ, Freund J et al (2008) The effects of high-intensity intermittent exercise training on fat loss and fasting insulin levels of young women. Int J Obes (Lond) 32:684–91.
Talanian JL, Galloway SD, Heigenhauser GJ et al (2007) Two weeks of high-intensity aerobic interval training increases the capacity for fat oxidation during exercise in women. J Appl Physiol 102:1439–47.PubMed
Burgomaster KA, Hughes SC, Heigenhauser GJ et al (2005) Six sessions of sprint interval training increases muscle oxidative potential and cycle endurance capacity in humans. J Appl Physiol 98:1985–90.PubMed
Goodpaster BH, Katsiaras A, Kelley DE (2003) Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes 52:2191–7.PubMed
Weston KS, Wisloff U, Coombes JS (2013) High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis. Br J Sports Med
Heggelund J, Nilsberg GE, Hoff J et al (2011) Effects of high aerobic intensity training in patients with schizophrenia: a controlled trial. Nord J Psychiatry 65:269–75.PubMedCentralPubMed
Abdel-Baki A, Brazzini-Poisson V, Marois F et al (2013) Effects of aerobic interval training on metabolic complications and cardiorespiratory fitness in young adults with psychotic disorders: A pilot study. Schizophr Res 149:112–5.PubMed
Pelham TW, Campagna PD, Ritvo PG et al (1993) The effects of exercise therapy on clients in a psychiatric rehabilitation program. Psychosocial Rehabilitation Journal 16:75–84.
Pajonk FG, Wobrock T, Gruber O et al (2010) Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry 67:133–43.PubMed
Marzolini S, Jensen B, Melville P (2009) Feasibility and effects of a group-based resistance and aerobic exercise program for individuals with severe schizophrenia: A multidisciplinary approach. Mental Health and Physical Activity 2:29–36.
Karlsen T, Helgerud J, Stoylen A et al (2009) Maximal strength training restores walking mechanical efficiency in heart patients. Int J Sports Med 30:337–42.PubMed
Nilsson BB, Westheim A, Risberg MA (2008) Effects of groupbased high-intensity aerobic interval training in patients with chronic heart failure. Am J Cardiol 102:1361–5.PubMed
Warburton DE, McKenzie DC, Haykowsky MJ et al (2005) Effectiveness of high-intensity interval training for the rehabilitation of patients with coronary artery disease. Am J Cardiol 95:1080–4.PubMed
Rognmo O, Hetland E, Helgerud J et al (2004) High intensity aerobic interval exercise is superior to moderate intensity exercise for increasing aerobic capacity in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil 11:216–22.PubMed
Daussin FN, Zoll J, Dufour SP et al (2008) Effect of interval versus continuous training on cardiorespiratory and mitochondrial functions: relationship to aerobic performance improvements in sedentary subjects. Am J Physiol Regul Integr Comp Physiol 295:R264–72.
Nemoto K, Gen-no H, Masuki S et al (2007) Effects of highintensity interval walking training on physical fitness and blood pressure in middle-aged and older people. Mayo Clin Proc 82:803–11.PubMed
Wallman K, Plant LA, Rakimov B et al (2009) The effects of two modes of exercise on aerobic fitness and fat mass in an overweight population. Res Sports Med 17:156–70.PubMed
Bartlett JD, Close GL, MacLaren DP et al (2011) High-intensity interval running is perceived to be more enjoyable than moderate-intensity continuous exercise: implications for exercise adherence. J Sports Sci 29:547–53.PubMed
Vancampfort D, De Hert M, Skjerven LH et al (2012) International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia. Disabil Rehabil 34:1–12.PubMed
De Hert M, Dekker JM, Wood D et al (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24:412–24.PubMed
Casey DE, Haupt DW, Newcomer JW et al (2004) Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 Suppl 7:4–18; quiz 19–20.PubMed
De Nayer A, De Hert M, Scheen A et al (2007) [Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics]. Encephale 33:197–202.PubMed
Saravane D, Feve B, Frances Y et al (2009) [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Encephale 35:330–9.PubMed
2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65:267–72.
Kinon BJ, Kaiser CJ, Ahmed S et al (2005) Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25:255–8.PubMed
Kaminsky LA, American College of Sports Medicine., American College of Sports Medicine (2010) ACSM’s health-related physical fitness assessment manual 3rd ed. Wolters Kluwer Health/Lippincott Williams & Wilkins Health, Philadelphia, pp xiii, 172
Ebbeling CB, Ward A, Puleo EM et al (1991) Development of a single-stage submaximal treadmill walking test. Med Sci Sports Exerc 23:966–73.PubMed
Mailey EL, White SM, Wojcicki TR et al (2010) Construct validation of a non-exercise measure of cardiorespiratory fitness in older adults. BMC Public Health 10–59.
Laboratories ATSCoPSfCPF (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–7.
Cohn TA, Sernyak MJ (2006) Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 51:492–501.PubMed
Vancampfort D, Probst M, Sweers K et al (2011) Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia. Acta Psychiatrica Scandinavica 123:423–430.PubMed
Kushi LH, Doyle C, McCullough M et al (2012) American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 62:30–67.PubMed
Kilbourne AM, Morden NE, Austin K et al (2009) Excess heartdisease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry 31:555–63.PubMedCentralPubMed
Graham I, Atar D, Borch-Johnsen K et al (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 14 Suppl 2:E1–40.
Gorczynski P, Faulkner G (2011) Exercise therapy for schizophrenia. Cochrane Database of Systematic Reviews
Vancampfort D, Knapen J, Probst M et al (2010) Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. Psychiatry Res 177:271–9.PubMed
Beebe LH, Burk R, McIntyre K et al (2009) Motivating Persons with Schizophrenia Spectrum Disorders to Exercise: Rationale and Design. Clin Schizophr Relat Psychoses 3:111–116.PubMedCentralPubMed
Nasrallah HA, Meyer JM, Goff DC et al (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86:15–22.PubMed
Bergqvist A, Karlsson M, Foldemo A et al (2013) Preventing the development of metabolic syndrome in people with psychotic disorders-difficult, but possible: experiences of staff working in psychosis outpatient care in sweden. Issues Ment Health Nurs 34:350–8.PubMed
Sorensen HJ, Mortensen EL, Parnas J et al (2006) Premorbid neurocognitive functioning in schizophrenia spectrum disorder. Schizophr Bull 32:578–83.PubMedCentralPubMed
Roberts SH, Bailey JE (2011) Incentives and barriers to lifestyle interventions for people with severe mental illness: A narrative synthesis of quantitative, qualitative and mixed methods studies. Journal of Advanced Nursing 67:690–708.PubMed
Howland RH (2007) Medication adherence. J Psychosoc Nurs Ment Health Serv 45:15–9.
Pijl H, Meinders AE (1996) Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf 14:329–42.
Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62 Suppl 7:22–31.PubMed
Blin O, Micallef J (2001) Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry 62 Suppl 7:11–21.PubMed
Birt J (2003) Management of weight gain associated with antipsychotics. Ann Clin Psychiatry 15:49–58.PubMed
Khazaal Y, Fresard E, Rabia S et al (2007) Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res 91:169–77.PubMed
Centorrino F, Wurtman JJ, Duca KA et al (2006) Weight loss in overweight patients maintained on atypical antipsychotic agents. Int J Obes (Lond) 30:1011–6.
Kalarchian MA, Marcus MD, Levine MD et al (2005) Behavioral treatment of obesity in patients taking antipsychotic medications. J Clin Psychiatry 66:1058–63.PubMed
Faulkner G, Soundy AA, Lloyd K (2003) Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 108:324–32.PubMed
Faulkner G, Cohn TA (2006) Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 51:502–11.PubMed
Faulkner G, Cohn T, Remington G (2007) Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev CD0051–8.
Borg GA (1974) Perceived exertion. Exerc Sport Sci Rev 2:131–53.PubMed